Ketogenic Diets: Cutting Weight, Raising Gut Cancer Risk

Eat the same meal and you might protect one inch of your intestine while endangering the next. Strange, right? A team at MIT reports exactly that paradox: a strict high-fat, very-low-carb diet can shrink tumor risk in the colon and simultaneously speed tumor growth in the small intestine.

Researchers working with genetically predisposed mice compared three diets: a classic ketogenic plan (high fat, minimal carbs), a standard control diet, and a high-fat, high-calorie regimen meant to induce obesity. The surprising result was not that fat was dangerous per se, but that where the fat’s effects showed up mattered enormously. Mice on the ketogenic diet did not become obese, yet they developed small-intestine tumors more often than controls and at rates similar to those fed the obesogenic diet.

So why would a diet linked in earlier studies to fewer colon tumors appear to worsen outcomes a few inches downstream? The MIT team dug into the cellular machinery and found an answer that sounds like metabolism talking to cell biology.

When the small intestine received an abundant supply of dietary fat, its lining began burning more of that fat through fatty acid oxidation. That shift turned on a family of regulators called PPARs—proteins that tune how cells process lipids and sense energy. Once activated, PPARs nudged intestinal stem cells into faster division. More divisions. More opportunity for mistakes. More opportunity for tumors.

The same high-fat, low-carb diet can suppress tumor growth in the colon while accelerating it in the small intestine.

Interestingly, the researchers found that ketone bodies—the molecules the body makes during ketosis, like beta-hydroxybutyrate—were not the villains or heroes here. Earlier work had pointed to ketones as possible suppressors of colon tumors, but in these experiments ketones behaved like metabolic bystanders. The real driver was how the intestinal stem cells processed dietary fat.

The colon tells a different metabolic story. In prior studies, including a 2022 paper, ketogenic feeding appeared to reduce colon tumor formation. But these new experiments suggest that ketone molecules themselves are not the direct agents of protection. Instead, tissue-specific metabolism—how local stem cells burn fuel and respond to surplus lipids—seems to explain the divergent outcomes between colon and small intestine.

Think of it as two neighbouring factories using the same shipment of fuel. One factory slows production when supply changes; the other revs up the assembly line. The second factory will produce more widgets—and more defects.

There are practical implications. People considering long-term ketogenic diets should know the picture is not uniformly positive or negative. Commercial ketone supplements, too, are unlikely to replicate either the protective effects reported for the colon or the tumor-promoting effects seen in the small intestine, because the key factor here is how cells metabolize dietary fat rather than circulating ketone levels.

Some groups may need to be especially cautious. Individuals with inherited conditions that raise intestinal cancer risk—familial adenomatous polyposis, for example—could be more vulnerable to diet-driven shifts in stem cell behavior. That concern is timely: small-intestine cancer rates have risen in recent decades, and these findings suggest diet may be one piece of a complex puzzle.

We still need answers. Why do neighboring tissues interpret the same metabolic signals so differently? Can we tweak diets to keep the benefits while avoiding the harms? For now, the study is a reminder that nutrition’s effects are nuanced, local, and sometimes surprising—so before adopting a strict regimen, ask which part of your body you’re feeding.